Ask This Startup Founder About His Transfer to COVID-19 Assessments

One small startup is stepping up within the battle towards COVID-19.

You’ll have by no means heard of 20/20 GeneSystems. However members of our First Stage Investor analysis service have. We beneficial they put money into 20/20 again in 2017.

And now 20/20 is doing one thing we couldn’t have predicted in 2017. This dynamic startup is gearing as much as present COVID-19 exams.

The corporate’s primary enterprise (and why we beneficial you put money into it within the first place) is layering synthetic intelligence excessive of blood exams to assist detect most cancers in its earliest phases.

An rising variety of individuals have used its exams right here within the U.S. I’ve taken the most cancers check myself. It’s the one check I do know that may inform me if I’m in peril of growing most cancers. (I examined optimistic.)

Like the remainder of the nation, 20/20 noticed the novel coronavirus explode within the U.S. and puzzled if it might assist. Now it’s transferring rapidly to convey a speedy COVID-19 blood check to the market within the U.S.

The corporate believes it will possibly assist repair the nation’s scarcity of COVID-19 exams. And it needs to seize a minimum of 5% of the COVID-19 testing market.

That is nice information for our nation. We desperately want the check that 20/20 is hoping to convey to market as quickly as subsequent week. It’s additionally excellent news for buyers. The corporate is in the midst of elevating funds. And proper now, you should buy its shares at a worth that was decided earlier than the coronavirus appeared. In different phrases, you’d be shopping for into an explosive development alternative at a closely discounted worth.

That is such an excellent alternative that we determined it shouldn’t be restricted simply to paying members of our startup analysis service. One of the simplest ways to share with you what the corporate is doing is to have you ever hear extra about it from the founder himself, Jonathan Cohen.

Early Investing, together with KingsCrowd (a San Francisco-based startup ranking firm), might be internet hosting an unique dwell webinar with Jonathan and his lieutenants this Thursday, April 2, from three p.m. to four p.m. ET (midday to 1 p.m. on the West Coast). Simply click on right here to register.

Jonathan might be answering these questions (amongst others)…

• What precisely is the speedy blood check 20/20’s making out there within the U.S.?
• What does it do this present swab exams don’t do?
• How huge is the marketplace for these exams?
• Who might be 20/20’s largest clients?
• How are you going to put money into 20/20’s present elevate?

The webinar will embrace a Q&A session, the place you’ll be able to ask Jonathan and his lieutenants something you need.

If you wish to study extra about this new check and distinctive funding alternative, simply click on right here to register. In the event you’ve already signed up, this serves as a reminder to affix us tomorrow at three p.m. ET.

20/20 GeneSystems illustrates how very small corporations can deal with very huge issues. And, many instances, they do it extra successfully than bigger corporations with extra assets and cash to attract upon.

This firm additionally represents the basic worth proposition of startups. Its shares go for a pittance. And for good motive. Attacking big issues typically ends in failure. However success is richly rewarded, for founders and early buyers alike.

20/20 GeneSystems is speeding to the help of a rustic in determined want of its exams. Whether or not or not you wish to make investments, its story alone is price listening to. However it’s additionally an opportunity to weigh a probably unbelievable funding alternative.

Hope to see you at our webinar starting tomorrow at three p.m. Click on right here if you happen to want to be part of us.